130 related articles for article (PubMed ID: 4089830)
1. Lack of correlation between "in vitro" and "in vivo" antithrombotic activity of heparin fractions and related compounds. Heparan sulfate as an antithrombotic agent "in vivo".
Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP
Thromb Res; 1985 Dec; 40(5):597-607. PubMed ID: 4089830
[TBL] [Abstract][Full Text] [Related]
2. Heparins and heparinoids: occurrence, structure and mechanism of antithrombotic and hemorrhagic activities.
Nader HB; Lopes CC; Rocha HA; Santos EA; Dietrich CP
Curr Pharm Des; 2004; 10(9):951-66. PubMed ID: 15078126
[TBL] [Abstract][Full Text] [Related]
3. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin.
Buchanan MR; Boneu B; Ofosu F; Hirsh J
Blood; 1985 Jan; 65(1):198-201. PubMed ID: 3965047
[TBL] [Abstract][Full Text] [Related]
4. Discordance between the anti-Xa activity and the antithrombotic activity in an ultra-low molecular weight heparin fraction.
Ockelford PA; Carter CJ; Mitchell L; Hirsh J
Thromb Res; 1982 Nov; 28(3):401-9. PubMed ID: 7179224
[TBL] [Abstract][Full Text] [Related]
5. Structural studies and "in vivo" and "in vitro" pharmacological activities of heparin fractions and fragments prepared by chemical and enzymic depolimerization.
Bianchini P; Osima B; Parma B; Dietrich CP; Takahashi HK; Nader HB
Thromb Res; 1985 Oct; 40(1):49-58. PubMed ID: 4089826
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges.
Walenga JM; Petitou M; Lormeau JC; Samama M; Fareed J; Choay J
Thromb Res; 1987 Apr; 46(2):187-98. PubMed ID: 3603420
[TBL] [Abstract][Full Text] [Related]
7. Fractionation and structural features of two heparin families with high antithrombotic, antilipemic and anticoagulant activities.
Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP; Casu B; Torri G
Arzneimittelforschung; 1985; 35(8):1215-9. PubMed ID: 4074437
[TBL] [Abstract][Full Text] [Related]
8. Studies on the antithrombotic effects and pharmacokinetics of heparin fractions and fragments.
Fareed J; Walenga JM; Williamson K; Emanuele RM; Kumar A; Hoppensteadt DA
Semin Thromb Hemost; 1985 Jan; 11(1):56-74. PubMed ID: 3883500
[TBL] [Abstract][Full Text] [Related]
9. The haemorrhagic and antithrombotic effects of dermatan sulphate.
Fernandez F; Van Ryn J; Ofosu FA; Hirsh J; Buchanan MR
Br J Haematol; 1986 Oct; 64(2):309-17. PubMed ID: 3778825
[TBL] [Abstract][Full Text] [Related]
10. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo.
Boneu B; Buchanan MR; Cade JF; Van Ryn J; Fernandez FF; Ofosu FA; Hirsh J
Thromb Res; 1985 Oct; 40(1):81-9. PubMed ID: 4089829
[TBL] [Abstract][Full Text] [Related]
11. Heparin from bovine intestinal mucosa: glycans with multiple sulfation patterns and anticoagulant effects.
Tovar AM; Capillé NV; Santos GR; Vairo BC; Oliveira SN; Fonseca RJ; Mourão PA
Thromb Haemost; 2012 May; 107(5):903-15. PubMed ID: 22437650
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of heparin fractions, fragments, and heparinoids.
Messmore HL
Semin Thromb Hemost; 1985 Apr; 11(2):208-12. PubMed ID: 2412297
[No Abstract] [Full Text] [Related]
13. Dextran sulfate included in factor Xa assay reagent overestimates heparin activity in patients after heparin reversal by protamine.
Mouton C; Calderon J; Janvier G; Vergnes MC
Thromb Res; 2003; 111(4-5):273-9. PubMed ID: 14693175
[TBL] [Abstract][Full Text] [Related]
14. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits.
Holmer E; Mattsson C; Nilsson S
Thromb Res; 1982 Mar; 25(6):475-85. PubMed ID: 7112507
[TBL] [Abstract][Full Text] [Related]
15. Demonstration of a direct anti-factor Xa activity in certain heparin-related glycosaminoglycans.
Larsson A; Fransson LA; Lewis WE
Thromb Res; 1982 Jun; 26(6):401-9. PubMed ID: 7112518
[TBL] [Abstract][Full Text] [Related]
16. Development of new heparin-like compounds and other antithrombotic drugs and their interaction with vascular endothelial cells.
Nader HB; Pinhal MA; Baú EC; Castro RA; Medeiros GF; Chavante SF; Leite EL; Trindade ES; Shinjo SK; Rocha HA; Tersariol IL; Mendes A; Dietrich CP
Braz J Med Biol Res; 2001 Jun; 34(6):699-709. PubMed ID: 11378657
[TBL] [Abstract][Full Text] [Related]
17. Comparative antithrombotic and hemorrhagic effects of dermatan sulfate, heparan sulfate and heparin.
Hoppensteadt D; Walenga JM; Fareed J
Thromb Res; 1990 Nov; 60(3):191-200. PubMed ID: 2084948
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of heparin and PK 10169, a low molecular weight fraction, in a canine model of arterial thrombosis.
Mestre M; Clairefond P; Mardiguian J; Trillou M; Le Fur G; Uzan A
Thromb Res; 1985 May; 38(4):389-99. PubMed ID: 4012669
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
Diness V; Ostergaard PB
Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
[TBL] [Abstract][Full Text] [Related]
20. In vivo effects of low molecular weight heparins on experimental thrombosis and bleeding.
Hirsh J
Haemostasis; 1986; 16(2):82-6. PubMed ID: 3710297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
